Janssen Halts the Development of Pimodivir for Influenza
Shots:
- The discontinuation is based on pre-planned interim analyses of P-III studies assessing Pimodivir + SOC vs SOC as monothx. in hospitalized & non-hospitalized patients with influenza A
- The therapy is unlikely to add benefits in hospitalized patients with influenza A. The company will halt both the studies- after consulting with BARDA
- In 2014- Janssen signed an exclusive license agreement with Vertex for the global development- manufacturing- and commercialization of pimodivir
Ref: Janssen | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com